Monjuvi from MorphoSys AG - long-term lymphoma use defines this classic

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 20:45. Details in the imprint.

Monjuvi is not the kind of cancer drug you notice on a pharmacy shelf - it lives in quiet hospital corridors, in infusion bags hanging beside the bed of someone whose lymphoma has already fought through standard therapy. The branded vials feel heavy in the nurse's gloved hand, because for many patients this CD19-directed antibody is the next, and perhaps last, line of defense.

Where Monjuvi fits in

Monjuvi, known as tafasitamab-cxix in the US, is a humanized monoclonal antibody targeting CD19 on B cells, approved in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.The official Monjuvi product page This position in the treatment cascade means oncologists typically use it after at least one line of therapy has failed, often after R-CHOP or similar regimens.

In practice, that translates to patients who may be older, more fragile, or carrying comorbidities that make high-dose chemotherapy and stem cell rescue too risky. When Dr. Jean-Paul Kress, CEO of MorphoSys, talks about Monjuvi, he regularly emphasizes this focus on an underserved population that needs options when standard tools run out.MorphoSys news and statements

How the regimen feels

Monjuvi is administered as an intravenous infusion, initially on an intense weekly schedule, then tapering over time, which shapes the rhythm of a patient's life around repeated hospital visits.FDA approval information for tafasitamab-cxix On infusion day, patients typically sit in a reclining chair for several hours, listening to pumps quietly tick while nurses check vitals and watch for infusion reactions, which are most common during the first doses.

The combination with lenalidomide adds an oral component: small capsules taken at home on a 28-day cycle. That mix of hospital-based infusions and self-managed oral therapy can be demanding but offers a structured routine. Many hematologists describe Monjuvi plus lenalidomide as a regimen that needs close monitoring but fits into existing infusion center workflows without requiring complex new equipment.

Clinical data that anchor use

The core of Monjuvi's positioning comes from the L-MIND study, a phase 2 trial that evaluated tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for autologous stem cell transplantation.Peer-reviewed L-MIND study publication in Blood Investigators reported notable overall response rates and durable remissions in a subset of patients, which helped convince regulators to grant approval.

For Dr. Gilles Salles, one of the principal investigators, the appeal of the regimen lies in its ability to deliver responses without the toxicity profile of aggressive salvage chemotherapy. He has described the antibody as a tool that, when paired with lenalidomide, can stabilize disease for meaningful periods in people who otherwise have limited paths forward.

Safety profile and monitoring

Like many immunotherapies, Monjuvi brings a safety profile dominated by hematologic toxicities such as neutropenia and anemia, along with infusion-related reactions and infections. That means regular blood counts, infection surveillance, and sometimes growth factor support become part of the routine.

Patients often hear their hematologist, not a marketing brochure, explain that fatigue and low counts are common but manageable with dose adjustments and supportive care. The goal is to keep the antibody on board long enough to achieve a deep response, without tipping the balance into unacceptable toxicity for already vulnerable patients.

Pricing and access realities

Monjuvi sits squarely in the high-cost oncology segment. In the United States, list prices for monoclonal antibodies used in lymphoma typically reach into several thousand dollars per vial, though actual costs depend on negotiated discounts and insurance coverage. For patients, the financial conversation can be as heavy as the clinical one.

MorphoSys and its US partner Incyte have put patient support programs in place, offering co-pay assistance and access initiatives for eligible individuals. In Europe, where the drug is marketed under the name Minjuvi, health technology assessments and price negotiations with national payers shape access, leading to varying availability and reimbursement conditions across countries.

How oncologists choose it

In daily practice, hematologists weigh Monjuvi against other options such as CAR-T cell therapies, polatuzumab-based regimens, or clinical trials. For patients too frail or otherwise unsuitable for CAR-T, the antibody plus lenalidomide combination offers a systemic, off-the-shelf approach available in standard infusion centers.

The decision often hinges on comorbidities, prior lines of therapy, and the speed of disease progression. Because Monjuvi is readily available once reimbursed, without the manufacturing queue that CAR-T requires, some physicians value the ability to start treatment quickly when a patient's disease is advancing.

Commercial life cycle as a longseller

For MorphoSys, Monjuvi represents a pivot from a pure licensing and antibody discovery business toward owning and managing a marketed oncology product. That transition brings recurring revenue streams but also long-term commercial responsibilities ranging from medical education to post-marketing safety commitments.

In investor presentations, Kress and his team point to Monjuvi's revenue trajectory and label expansions as key elements of the company's strategy. The product may not grab headlines like a newly launched CAR-T platform, yet its steady presence in lymphoma centers makes it a classic rather than a fleeting launch.

What matters for investors

MorphoSys is headquartered in Planegg near Munich and remains listed in Germany and the US, giving international investors exposure to its oncology portfolio. Monjuvi's performance influences expectations around the company's ability to generate sustainable cash flows while developing new therapies.

Overall, this long-established drug keeps the MorphoSys shares (ISIN DE0006632003) closely watched on Xetra, where oncology data, reimbursement decisions, and competitive pressure from other lymphoma treatments can all color how the market values the company's pipeline and its marketed assets.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.